Abstracts Archive - Page 1880 of 2607 - ACR Meeting Abstracts

Abstract Number: 128 • 2015 ACR/ARHP Annual Meeting
Economic Burden and Treatment Patterns of Cycling Between Non-Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs) Among Patients with Rheumatoid Arthritis (RA)
Nanxin Li¹, Keith Betts¹, Jenny Griffith², Ljubica Ristovska¹, Kevin Douglas² and Arijit Ganguli², ¹Analysis Group, Inc., Boston, MA, ²AbbVie Inc., North Chicago, IL
Background/Purpose: RA patients with inadequate treatment response often cycle non-biologic DMARDs before initiating a biologic DMARD. Early and aggressive treatment is a key feature of…
Abstract Number: 129 • 2015 ACR/ARHP Annual Meeting
Rheumatologists’ Approaches to Diagnosis and Treatment of Depression
Erica Heiman, Barton Wise and Richard L. Kravitz, Department of Internal Medicine, UC Davis Medical Center, Sacramento, CA
Background/Purpose: Depression in patients with rheumatic disorders contributes to morbidity, mortality, and health care utilization. We set out to examine rheumatologists’ approaches to and perceptions…
Abstract Number: 130 • 2015 ACR/ARHP Annual Meeting
Disease Activity Patterns in Incident Onset Rheumatoid Arthritis Patients in the First 3-Years of Follow up
Mark Tatangelo¹, George A. Tomlinson², Bindee Kuriya³ and Claire Bombardier⁴, ¹University of Toronto, Toronto, ON, Canada, ²Medicine, Mount Sinai Hospital, Toronto, ON, Canada, ³Rheumatology, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ⁴Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada
Background/Purpose: Disease progression in longitudinal studies of rheumatoid arthritis (RA) is usually assessed by examining a measure of disease over time fixed time intervals. We…
Abstract Number: 131 • 2015 ACR/ARHP Annual Meeting
Frequency of Lipid Testing and Management Among Rheumatoid Arthritis Patients Compared to the General Population and Patients with Diabetes
Iris Navarro-Millan¹, Shuo Yang², Monica Safford³, Lang Chen³, Huifeng Yun⁴ and Jeffrey R. Curtis³, ¹Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ²Clinical Immunology/Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ³University of Alabama at Birmingham, Birmingham, AL, ⁴Epidemiology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Patients with rheumatoid arthritis (RA) have high coronary heart disease (CHD) burden and accelerated atherosclerotic status. However, limited data suggest that these patients may…
Abstract Number: 132 • 2015 ACR/ARHP Annual Meeting
Delivering a One-Stop, Integrated, Patient-Centred Service for Patients with Rheumatic Diseases. the Finnish Approach
Elena Nikiphorou¹, Paula Väre¹, Kirsi Paalanen¹, Jelena Borodina¹, Arto Kokko², Pekka Hannonen¹ and Tuulikki Sokka-Isler³, ¹Jyvaskyla Central Hospital, Jyvaskyla, Finland, ²Jyvaskyla Central Hospital, Jyväskylä, Finland, ³Rheumatology, Jyvaskyla Central Hospital, Jyvaskyla, Finland
Background/Purpose: Rheumatology is mainly an outpatient specialty. Prompt diagnosis & treatment to prevent long-term disability in an integrated, multi-disciplinary approach to care are crucial. In reality though,…
Abstract Number: 133 • 2015 ACR/ARHP Annual Meeting
Advocating for Rheumatoid Arthritis and Cardiovascular Health (ARCH) in a Tertiary Referral Center: A Collaborative and Systems-Based Approach to Improve Access to Care
Barbara Goldstein¹, JoAnn Zell¹, Pearlanne Zelarney², Matthew Stern², Sarah Meadows², Meg Dingae², Carmen Egidio² and Darlene Kim², ¹Medicine, National Jewish Health, Denver, CO, ²National Jewish Health, Denver, CO
Background/Purpose: Patients with rheumatoid arthritis (RA) have an increased risk of cardiovascular disease (CVD) as compared to the general population. The European League Against Rheumatism…
Abstract Number: 134 • 2015 ACR/ARHP Annual Meeting
Axial Spondyloarthritis: Validation of an Inter-Professional Model of Care
Christopher Hawke¹, Laura Passalent^2,3, Anthony V. Perruccio⁴, Kala Sundararajan⁵, Nigil Haroon⁶, Robert D Inman⁷ and Y. Raja Rampersaud⁸, ¹Toronto Western Hospital, University of Toronto, Toronto, ON, Canada, ²Allied Health, Toronto Western Hospital, Toronto, ON, Canada, ³Physical Therapy, University of Toronto, Toronto, ON, Canada, ⁴Orthopaedic Surgery, Brigham & Women's Hospital and Harvard Medical School, Boston, MA, ⁵Orthopaedic Research Department, Toronto Western Hospital, Toronto, ON, Canada, ⁶Rheumatology, Toronto Western Hospital, University of Toronto, Toronto, ON, Canada, ⁷Immunlogy and Institute of Medical Science, Toronto Western Hospital, University of Toronto, Toronto, ON, Canada, ⁸Orthopaedic Surgery and Neurosurgery, University Health Network and University of Toronto, Toronto, ON, Canada
Background/Purpose: Early detection of axial Spondyloarthritis (axSpA) is challenging given the lack of pathognomonic clinical findings. Clinical overlap with mechanical back pain leaves axSpA a…
Abstract Number: 135 • 2015 ACR/ARHP Annual Meeting
Limitations of Treat-to-Target in Rheumatoid Arthritis: Joint Damage Appears As Severe As Inflammation in Contemporary Care at One Site
Theodore Pincus¹, Alex D. Luta², Isabel Castrejón¹, Annie Huang¹, Ruchi Jain¹, Sarah L. Everakes³ and Joel A. Block⁴, ¹Rheumatology, Rush University Medical Center, Chicago, IL, ²Georgetown University, Washington, DC, ³Internal Medicine, Rush University Medical Center, Chicago, IL, ⁴Rush University Medical Center, Chicago, IL
Background/Purpose: Treatment of rheumatoid arthritis is directed to “treat-to-target,” with intensification of therapy in patients with moderate/high disease activity according to a quantitative index toward…
Abstract Number: 136 • 2015 ACR/ARHP Annual Meeting
Physician Patterns of Patient Care in Systemic Lupus Erythematosus: Are We Ordering Unnecessary Tests?
Aman Kugasia¹, Meenakshi Jolly², Winston Sequeira³, Ailda Nika³, Neha Sehgal⁴ and Mary Dollear⁵, ¹Internal Medicine, John H Stroger Hospital of Cook County, Chicago, IL, ²Department of Medicine, Section of Rheumatology, Rush University Medical Center, Chicago, IL, ³Rheumatology, Rush University Medical Center, Chicago, IL, ⁴Indiana University- Bloomington, Valparaiso, IN, ⁵Vice President, Lupus Society of Illinois, Chicago, IL
Background/Purpose: To plan a quality improvement project, we need to understand the practice patterns of physicians. We undertook an online survey of physicians (MDs) (Rheumatologists,…
Abstract Number: 137 • 2015 ACR/ARHP Annual Meeting
Willingness to Pay for Highly Effective Drug Treatments in Brazilian Rheumatoid Arthritis Patients
Cleandro Albuquerque¹, Pedro Haddad², Vander Fernandes³, Claudia Marques⁴, Sonia Fialho⁵, Adriana Kakehasi⁶, Fabio Jennings⁷, Claiton Brenol⁸, Lícia M. H. Mota^9,10, Geraldo Castelar-Pinheiro^2,11, Angela Duarte¹², Iara Giroto¹³, Maria Raquel C. Pinto¹⁴, Mariana Toni¹⁵, Mirhelen Mendes Abreu¹⁶ and Marcos B. Ferraz¹⁷, ¹Rheumatology, Hospital Universitário de Brasília - UnB, Brasília, Brazil, ²Universidade do Estado do Rio de Janeiro - UERJ, Rio de Janeiro, Brazil, ³Universidade de Cuiabá, Cuiaba MT, Brazil, ⁴Disciplina de Reumatologia, Hospital das Clínicas - Universidade Federal de Pernambuco, Recife - PE, Brazil, ⁵Rodovia Virgílio Várzea 1510 B, Universidade Federal de Santa Catarina, Florianópolis, Brazil, ⁶Rua Astolfo Vieira de Resende, Faculdade de Medicina - UFMG, Belo Horizonte, Brazil, ⁷Disciplina de reumatologia, Universidade Federal de São Paulo, Sao Paulo, Brazil, ⁸Universidade Federal do Rio Grande do Sul, Porto Alegre RS, Brazil, ⁹Rheumatology, University Hospital, Faculty of Medicine, University of Brasília, Brasília/DF, Brazil, ¹⁰Hospital Universitário de Brasília - UnB, Brasília, Brazil, ¹¹Discipline of Rheumatology, Rio de Janeiro State University, Rio de Janeiro, Brazil, ¹²Internal Medicine, Hospital das Clínicas - UFPE, Recife, Brazil, ¹³Universidade de Cuiabá, Cuiabá, Brazil, ¹⁴Universidade Federal de Minas Gerais, Belo Horizonte, Brazil, ¹⁵Faculdade de Medicina - UFRGS, Porto Alegre, Brazil, ¹⁶Disciplina de Reumatologia, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil, ¹⁷Universidade Federal de São Paulo, São Paulo, Brazil
Background/Purpose: Willingness to pay (WTP) is a technique used for valuing health benefits and individual preferences. Brazil’s national public health system (Sistema Único de Saúde)…
Abstract Number: 138 • 2015 ACR/ARHP Annual Meeting
Identification and Documentation of Secondary Osteoarthritis in Patients with Primary Inflammatory Arthritides Using a Patient MDHAQ/RAPID3 and a Physician Estimate of Joint Damage to Recognize Patient Complexity and Inform Management Decisions
Kathryn A. Gibson¹, Annie Huang², Katherine J. Bryant³ and Theodore Pincus², ¹Liverpool Hospital, Liverpool, Australia, ²Rheumatology, Rush University Medical Center, Chicago, IL, ³University of New South Wales, Sydney, Australia
Background/Purpose: Patients with inflammatory arthritides may have secondary osteoarthritis (OA), which affects decisions concerning clinical management. For example, in one study, about 20% of patients…
Abstract Number: 139 • 2015 ACR/ARHP Annual Meeting
One-Year Cost of Etanercept, Adalimumab, and Infliximab per Treated Patient with Chronic Inflammatory Arthritides in US Veterans
Brian Sauer¹, Chia-Chen Teng², Tao He³, Jianwei Leng⁴, Chao-Chin Lu⁵, Jessica Walsh⁶, Neel Shah⁷, David J. Harrison⁸, Derek Tang⁹ and Grant W. Cannon¹⁰, ¹IDEAS Center and Division of Epidemiology, HSR&D SLC VA Medical Center and University of Utah, Salt Lake City, UT, ²HSR&D SLC VA Medical Center and University of Utah, Salt Lake City, UT, ³Salt Lake City Veteran Affairs and University of Utah Medical Centers, Salt Lake City, UT, ⁴Internal Medicine Division of Epidemiology, HSR&D SLC VA Medical Center and University of Utah, Salt Lake City, UT, ⁵Salt Lake City VA and University of Utah, Salt Lake City, UT, ⁶Division of Rheumatology, Salt Lake City Veteran Affairs and University of Utah Medical Centers, Salt Lake City, UT, ⁷1 Amgen Center Dr, Amgen Inc., Thousand Oaks, CA, ⁸Amgen Inc., Thousand Oaks, CA, ⁹Amgen, Inc., Thousand Oaks, CA, ¹⁰Division of Rheumatology, Salt Lake City VA Medical Center and University of Utah, Salt Lake City, UT
Background/Purpose: Understanding the relative cost of tumor necrosis factor inhibitors (TNFi) can improve resource allocation from a payer’s perspective. Limited data exists in the VA…
Abstract Number: 140 • 2015 ACR/ARHP Annual Meeting
Identifying Psoriatic Arthritis and Ankylosing Spondylitis Patients Responsible for the Highest Costs of Care: Data from a Large US Cohort
Jacqueline B. Palmer, Yunfeng Li, Vivian Herrera and Minlei Liao, Novartis Pharmaceuticals Corporation, East Hanover, NJ
Background/Purpose: The economic burden of psoriatic arthritis (PsA) and ankylosing spondylitis (AS) in the biologics era is not well understood in the US population. Using…
Abstract Number: 141 • 2015 ACR/ARHP Annual Meeting
Improved Follow-up of Hypertension in Rheumatology Patients: Results of a Pilot
Christie M. Bartels¹, Edmond Ramly², Heather Johnson³, Yingqi Zhao¹, Zhanhai Li⁴, Patrick McBride³, Kristin Steffen Lewicki¹ and Diane Lauver⁵, ¹Department of Medicine, University of Wisconsin (UW) School of Medicine and Public Health (SMPH), Madison, WI, ²Industrial and Systems Engineering, University of Wisconsin-Madison College of Engineering, Madison, WI, ³Cardiology/Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, ⁴University of Wisconsin (UW) School of Medicine and Public Health (SMPH), Madison, WI, ⁵University of Wisconsin-Madison School of Nursing, Madison, WI
Background/Purpose: Hypertension is the most common and most modifiable cardiovascular disease (CVD) risk factor, yet it is uncontrolled in ½ of US adults. Hypertension management…
Abstract Number: 142 • 2015 ACR/ARHP Annual Meeting
Exploration of General Practioners’ Difficulties with Methotrexate and Anti-TNF Therapies in Routine Practice
Elise Berthet¹, Virginie Moiroud², Marion De Rosa², Martin Soubrier³ and Sylvain Mathieu⁴, ¹Rheumatology, CHU Gabriel Montpied, Clermont-Ferrand, France, ²Médecine Générale, CHU Gabriel Montpied, Clermont-Ferrand, France, ³Rheumatology department CHU Clermont-Ferrand, Clermont-Ferrand, France, ⁴Rheumatology Department, CHU clermont-Ferrand, Clermont-Ferrand, France
Background/Purpose: Chronic inflammatory arthritis affects around 1% of the general population. Disease-modifying drugs like methotrexate (MTX) and in second-line anti tumor necrosis factor (anti-TNF) therapy…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].